Venous Thromboembolism Prevention During Asparaginase-Based Therapy for Acute Lymphoblastic Leukemia | Zendy

Hassan Sibai | Zendy; Jack T Seki | Zendy; T.Q. Wang | Zendy; Naoki Sakurai | Zendy; Eshetu G. Atenafu | Zendy; Karen Yee | Zendy; Andre C. Schuh | Zendy; Vikas Gupta | Zendy; Mark D. Minden | Zendy; Aaron D. Schimmer | Zendy; Joseph Brandwein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Venous Thromboembolism Prevention During Asparaginase-Based Therapy for Acute Lymphoblastic Leukemia

Author(s) -

Hassan Sibai,

Jack T Seki,

T.Q. Wang,

Naoki Sakurai,

Eshetu G. Atenafu,

Karen Yee,

Andre C. Schuh,

Vikas Gupta,

Mark D. Minden,

Aaron D. Schimmer,

Joseph Brandwein

Publication year - 2016

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.23.3077

Subject(s) - medicine , regimen , asparaginase , chemotherapy , venous thrombosis , thrombosis , low molecular weight heparin , surgery , complication , chemotherapy regimen , lymphoblastic leukemia , leukemia

Venous thromboembolism (vte) is a recognized complication in patients treated with asparaginase-containing chemotherapy regimens; the optimal preventive strategy is unclear. We assessed the safety and efficacy of prophylaxis using low-dose low molecular weight heparin in adult patients with acute lymphoblastic leukemia in complete remission treated with an asparaginase-based post-remission chemotherapy regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research